Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 812-927-5 | CAS number: 1902936-62-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
OECD 408 - NOAEL >= 1000 mg/kg bw/d (no adverse effects observed)
OECD 422 - NOAEL >= 1000 mg/kg bw/d (no adverse effects observed)
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- July 2021 - June 2022
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Reason / purpose for cross-reference:
- reference to other study
- Remarks:
- dose-range finding study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- 25 June 2018
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on species / strain selection:
- The Sprague Dawley SD rat was the species and strain of choice because it is accepted by many regulatory authorities and there are ample experience and background data on this species and strain. The experimental laboratory has sufficient historical control data for the strain used.
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: ordered from Envigo RMS srl, San Pietro al Natisone (UD), Italy and supplied by Envigo RMS B.V., Kreuzelweg 53, 5961 NM Horst, Netherlands
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: 27-29 days old
- Weight at study initiation: 95-121 g for males and 91-113 g for females
- Fasting period before study: no
- Housing: up to 5 of one sex in a cage (in clear polysulfone solid bottomed cages)
- Diet (e.g. ad libitum): 4 RF 21,Mucedola S.r.l., Via G. Galilei 4, 20019 SettimoMilanese (MI), Italy) was offered ad libitum
- Water (e.g. ad libitum): drinking water ad libitum
- Acclimation period: 12 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22°C ± 2°C
- Humidity (%): 55% ± 15%
- Air changes (per hr): approx. 15-20
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 01-July-2021 (Arrival of animals) To: 13--Oct-2021 (Last day of necropsy) - Route of administration:
- oral: gavage
- Details on route of administration:
- Oral administration is adequate since the substance is not handled in inhalable form and dermal penetration is not expected based on the data available. The oral route has been selected as it has been specifically requested by the Regulatory Authorities.
- Vehicle:
- CMC (carboxymethyl cellulose)
- Remarks:
- 0.5 % aqueous carboxymethylcellulose (0.5% CMC)
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The required amount of test item was suspended in the vehicle.
The preparations were made daily/weekly (concentrations of 10, 30 and 100 mg/mL).
Concentrations were calculated and expressed in terms of test item as supplied. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Analysis was performed in a separate study in order to validate the analytical method and the preparation procedure and to verify the stability of the preparations.
The analytical method was validated in the range from 10 to 100 mg/mL. Linearity, accuracy and precision were within the limits stated in the validation protocol (r > 0.995; accuracy 85-115%; precision CV < 10%).
A 27 hour stability at room temperature and an 8 day stabiliy at 2-8°C were verified in the range from 10 to 100 mg/mL. Suspensions are considered to be stable if concentration and homogeneity are still acceptable (85%-115% for concentration and CV < 10% for homogeneity) after the defined period of storage.
The proposed preparation procedure for the test item was checked in the range from 10 to 100 mg/mL by chemical analysis (concentration and homogeneity) to confirm that the method was suitable. Final results for all levels were within the acceptability limits for concentration (85-115%) and homogeneity (CV < 10%).
Samples of the suspensions prepared on Week 1 (Day 1) and Last week (Day 86) were analysed to check their homogeneity and concentration. Results of the analyses were within the acceptability limits for suspensions (85-115% for concentration and CV < 10% for homogeneity) and are available.
The validated software used for this activity was Chromeleon. - Duration of treatment / exposure:
- 13 weeks
- Frequency of treatment:
- daily
- Dose / conc.:
- 100 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Dose levels have been selected based on the results obtained in a previous oral toxicity study in rats, performed according to OECD Guideline 422 - Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test. In this study, no adverse effects were noted at all dose levels (100, 300 and 1000 mg/kg bw/day) and the dose level ≥ 1000 mg/kg bw/day was considered the NOAEL in this study. Therefore, the doses were selected to include the limit dose of 1000 mg/kg bw/d and dose spacing of ca. 3 was used as standard dose spacing.
- Dose range finding studies: please refer to cross-referenced study according to OECD Guideline 422 - Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Animals were checked for mortality twice per day on weekdays and once per day on weekends and public holidays. Observations for clinical signs were conducted once per day after dosing.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Once before commencement of treatment and at least once per week during the study. Each animal was observed in an open arena. The test included observation and record of changes in gait and posture, reactivity to handling, presence of clonic or tonic movements, stereotypies or bizarre behaviour and effects on the autonomic nervous system (e.g. lachrymation, piloerection, unusual respiratory pattern). Changes in fur, skin, eyes, mucous membranes, occurrences of secretions and excretions was also recorded.
BODY WEIGHT: Yes
- Time schedule for examinations: day of allocation to treatment group, start of treatment, weekly thereafter and just prior to necropsy
FOOD CONSUMPTION:
- TIme schedule: recorded at weekly intervals starting from treatment (the group mean daily intake per rat was calculated). Measurements were performed by cage.
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: all animals were examined prior to the commencement of treatment, eyes of all animals from high dose and control groups were re-examined during Week 13 of treatment
SERUM HORMONES: Yes
- Time of blood sample collection: last week of treatment
- Animals fasted: Yes
- How many animals: all
- Hormone parameters: T3, T4, TSH (determined by RadioImmuneAssay (RIA))
HAEMATOLOGY: Yes
- Time schedule for collection of blood: prior to necropsy
- Anaesthetic used for blood collection: Yes (isoflurane)
- Animals fasted: Yes
- How many animals: all
- Parameters examined: Haematocrit, Haemoglobin, Red blood cell count, Reticulocyte count, Mean red blood cell volume, Mean corpuscular haemoglobin, Mean corpuscular haemoglobin concentration, White blood cell count, Differential leucocyte count (Neutrophils, Lymphocytes, Eosinophils, Basophils, Monocytes, Large unstained cells), Platelets, Coagulation (Prothrombin time, APTT)
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: prior to necropsy
- Animals fasted: Yes
- How many animals: all
- Parameters examined: Alkaline phosphatase, Alanine aminotransferase, Aspartate aminotransferase, Gamma-glutamyltransferase, Urea, Blood urea nitrogen, Creatinine, Glucose, Triglycerides, Inorganic phosphorus, Total bilirubin, Total cholesterol, HDL, LDL, Total protein, Albumin, Globulin, A/G Ratio, Sodium, Potassium, Calcium, Chloride
OESTROUS CYCLE: YES
- Time schedule: at the end of the treatment and just prior to necropsy, vaginal smears were taken from all animals
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: Once during weeks 13 of treatment
- Dose groups that were examined: all
- Battery of functions tested: sensory activity (e.g. auditory, visual and proprioceptive stimuli) / grip strength / motor activity (at 10 minute intervals over 60 minutes)
URINALYSIS: NO
IMMUNOLOGY: NO - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes
Samples of all the tissues listed below were fixed and preserved in 10% neutral buffered formalin (except eyes, optic nerves, Harderian glands, testes and epididymides which were fixed inModified Davidson’s fluid and preserved in 70% ethyl alcohol).
TISSUES PROCESSED:
see "any other information on methods including tables" - Statistics:
- Standard deviations were calculated as considered appropriate. For continuous variables the significance of the differences amongst groups was assessed by analysis of variance.
Differences between each treated group and the control group were assessed by Dunnett’s test using a pooled error variance. The homogeneity of the data was verified by Bartlett’s test before Dunnett’s test. If the data were found to be inhomogeneous aModified t test (Cochran and Cox) was applied.
The mean values, standard deviations and statistical analysis were calculated from the actual values in the computer without rounding off. - Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No treatment-related clinical signs were observed.
100 mg/kg bw/d, 1 male animal: Ocular transparent discharge and coloured staining around both eyelid in some occasions during the study
--> considered unrelated to treatment with the test item (absence of a dose-relation and other clinical signs)
No treatment-related changes were observed at the weekly clinical examination, which included an evaluation of neurotoxicity
100 mg/kg bw and 300 mg/kg bw, males and females: slight fluctuations in the number of rearing events during dosing period in a single occiasion
1000 mg/kg bw, males and females: occasional decrease in the number of rearing evens
--> not considered to be treatment-related (absence of a clear dose-relation and episodical occurence) - Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- When compared to control animals, no changes were noted in mean body weights and
body weight gain in both genders during the study. - Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- No treatment-related changes were observed in food consumption in male and female
animals, during the study. - Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Description (incidence and severity):
- No findings were detected in both eyes of all animals, from high dose and control groups,
following examination performed duringWeek 13 of treatment. - Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- 100 mg/kg bw, males: higher monocytes (+78%)
--> considered to be incidental (within the range of historical data)
1000 mg/kg bw males: lower erythrocytes (-5%)
--> considered to be non-adverse (5/10 animals slightly below the historical data and slight severity of the effect; even though the relation with the test item cannot be definitively excluded)
1000 mg/kg bw, females: higher leucocytes (+41%)
--> considered to be incidental (within the range of historical data) - Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No treatment-related changes were recorded
300 and 1000 mg/kg bw, males: higher inorganic phosphorous (14% and 15%, respectively; 3/10 and 4/10 animals outside of historical date, respectively)
--> considered to be incidental (slight severity, absence of other related findings)
1000 mg/kg bw, females: decreased chloride (-2%)
--> considered to be incidental (within the range of historical data) - Endocrine findings:
- no effects observed
- Description (incidence and severity):
- Thyroid hormone determination: no changes were recorded.
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- effects observed, non-treatment-related
- Description (incidence and severity):
- No differences that could be considered treatment-related were observed at functional tests (sensory reaction to stimuli, landing footsplay, grip strength, motor activity) performed at the end of the treatment period.
300 and 1000 mg/kg bw, males and females: lower values in males and higher values in females of grip strength measurement (first, second trials and mean values)
--> considered to be incidental (absence of a clear dose-relation and to the inconsistency of the variations (higher or lower)
No treatment-related changes were observed at the weekly clinical examination, which included an evaluation of neurotoxicity
100 mg/kg bw and 300 mg/kg bw, males and females: slight fluctuations in the number of rearing events during dosing period in a single occiasion
1000 mg/kg bw, males and females: occasional decrease in the number of rearing events
--> not considered to be treatment-related (absence of a clear dose-relation and episodical occurence) - Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Description (incidence and severity):
- All differences between the test item-treated groups and controls were small, never reached
statistical significance and were interpreted to reflect individual variations. - Gross pathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- All macroscopic observations were spontaneous in nature and bore no relationship to
treatment. - Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- 1000 mg/kg bw, males and females: aggregates of large eosinophilic macrophages in the sinuses of mesenteric lymph nodes with a score up to moderate
300 mg/kg bw, 1 female: aggregates of large eosinophilic macrophages in the sinuses of mesenteric lymph nodes with a minimal severity
--> possibly reflects accumulation of the test item; considered non adverse (due to absence of other changes in the node architecture and of associated clinical pathology changes)
1000 mg/kg bw, females: higher incidence and severity of squamous metaplasia of uterine glands
--> spontaneous squamous metaplasia is rare (indeed a higher incidence than usual is noted in controls and at intermediate dose levels in the present study); relationship to treatment cannot be completely excluded but increased incidence is likely a chance event given the high background in this study and the absence of differences in ovarian cycle distribution between control and high dose groups - Histopathological findings: neoplastic:
- no effects observed
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Critical effects observed:
- no
- Conclusions:
- On the basis of the above results and under the conditions tested, no adverse effects were observed at all dose levels investigated following treatment with the test substance when administered by oral gavage for 13 consecutive weeks at the dosages of 100, 300 and 1000 mg/kg/day, when compared to controls. Therefore, it can be concluded that the No Observed Adverse Effect Level (NOAEL) for this study is 1000 mg/kg/day.
- Executive summary:
The test substance was tested in a GLP-conform OECD TG 408 study:
The toxicity of the test substance was investigated in Sprague Dawley SD rats after daily oral administration for 13 weeks.
Three groups, each of 10 male and 10 female rats, received the test item by gavage at dosages of 100, 300 and 1000 mg/kg/day for 13 consecutive weeks. A fourth similarly constituted group received the vehicle alone (0.5% aqueous carboxymethylcellulose) and acted as a control. All doses were administered at a constant volume of 10 mL/kg body weight.
The following investigations were performed: mortality and morbidity check, daily clinical signs, weekly detailed clinical signs (removal from cage and open field observations), evaluation of sensory reactivity to stimuli and motor activity, body weight, food consumption, oestrus cycle evaluation, ophthalmoscopy, clinical pathology investigations (including haematology and coagulation, clinical chemistry and thyroid hormones determination), terminal body weight, organ weights, macroscopic observations and microscopic examination, which included the identification of the stages of the spermatogenic cycle and the evaluation of the oestrus cycle.
No mortality occurred and no treatment-related clinical signs were observed during the study.
No relevant changes in detailed clinical observation, that can be considered related to treatment, were observed in animals at removal from cage and in an open arena. No treatment-related changes were observed in treated animals at functional tests (sensory reaction to stumuli, landing foot splay, grip strength). No treatment-related differences were noted in the motor activity measurements.
Body weight, food consumption and oestrus cycle were not affected by treatment.
No treatment-related findings in opthalmoscopy were recorded.
No changes in haematology and coagulation which were considered to be adverse were observed. The statistically significant differences of monocytes in males and leucocytes in females were of slight severity and incidence, therefore they were considered to be incidental. The decrease of erythrocytes recorded in males dosed at 1000 mg/kg/day was considered to be non-adverse, even though the relation with the test item cannot be definitively excluded.
No treatment-related changes were recorded in coagulation and clinical chemistry.
No treatment-related changes were recorded in thyroid hormone determination.
No changes in organ weights or macroscopic effects were noted.
In microscopic observations, aggregates of large macrophages were observed in both sexes in mesenteric lymph nodes at the dose of 1000 mg/kg/day, and in a single female at the dose of 300 mg/kg/day. This change was considered non-adverse. A high incidence of squamous metaplasia of the uterus was observed at 1000 mg/kg/day, in a context of an unusually high prevalence of this finding in the study, including in control animals. It was therefore considered a chance event, unrelated to the test item.
On the basis of the above results and under the conditions tested, no adverse effects were observed at all dose levels investigated following treatment with the test substance when administered by oral gavage for 13 consecutive weeks at the dosages of 100, 300 and 1000 mg/kg/day, when compared to controls. Therefore, it can be concluded that the No Observed Adverse Effect Level (NOAEL) for this study is 1000 mg/kg/day.
Reference
Table 1: Clinical Signs - Group Incidence
Males | Females | ||||||||||||||||||
Dosing | Dosing | ||||||||||||||||||
Dose group [mg/kg bw/d] | 0 | 100 | 300 | 1000 | Dose group [mg/kg bw/d] | 0 | 100 | 300 | 1000 | ||||||||||
Number of Animals | 10 | 10 | 10 | 10 | Number of Animals | 10 | 10 | 10 | 10 | ||||||||||
Number Examines | 10 | 10 | 10 | 10 | Number Examines | 10 | 10 | 10 | 10 | ||||||||||
Category | Observation | a | b | a | b | a | b | a | b | Category | Observation | a | b | a | b | a | b | a | b |
No significant signs | No significant signs | 10 | 92.5 | 10 | 88.5 | 10 | 92.5 | 10 | 92.5 | No significant signs | No significant signs | 10 | 92.5 | 10 | 92.5 | 10 | 92.5 | 10 | 92.5 |
APPEARANCE | Staining, Both eyelids, Right, Moderate, Brown | 0 | 0 | 1 | 2.0 | 0 | 0 | 0 | 0 | ||||||||||
Staining, Both eyelids, Right, Slight, Brown | 0 | 0 | 1 | 18.0 | 0 | 0 | 0 | 0 | |||||||||||
Staining, Both eyelids, Right, Slight, Red | 0 | 0 | 1 | 1.0 | 0 | 0 | 0 | 0 | |||||||||||
Staining, Eye, Slight, Brown | 0 | 0 | 1 | 1.0 | 0 | 0 | 0 | 0 | |||||||||||
EYE - EAR - MOUTH-NOSE | Ocular discharge, Right, Transparent | 0 | 0 | 1 | 19.0 | 0 | 0 | 0 | 0 |
a - number of animals affected
b - number of days with clinical sign/animal
Table 2: Body Weight - Group mean data
Males | ||||||||||||||||
Quarantine | Dosing | |||||||||||||||
Dose [mg/kg bw/d] | Body Weight (g) | Day 8 | Day 1 | Day 8 | Day 15 | Day 22 | Day 29 | Day 36 | Day 43 | Day 50 | Day 57 | Day 64 | Day 71 | Day 78 | Day 85 | Day 92 |
0 | (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Mean | 150.68 | 186.47 | 236.80 | 281.32 | 312.78 | 339.15 | 357.60 | 374.00 | 388.44 | 396.51 | 408.26 | 417.40 | 431.78 | 435.04 | 432.00 | |
SD | 8.827 | 9.996 | 10.988 | 10.767 | 11.486 | 13.274 | 15.547 | 15.206 | 13.864 | 12.825 | 14.220 | 14.139 | 15.681 | 15.028 | 21.392 | |
100 | (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Mean | 150.30 | 186.64 | 239.17 | 287.20 | 318.98 | 345.68 | 369.36 | 388.32 | 402.51 | 410.19 | 422.80 | 429.83 | 442.59 | 445.40 | 448.40 | |
SD | 8.248 | 12.746 | 13.754 | 17.390 | 17.693 | 21.583 | 22.035 | 23.355 | 21.654 | 22.082 | 24.324 | 22.781 | 21.309 | 22.948 | 30.329 | |
300 | (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Mean | 150.10 | 184.05 | 235.98 | 280.84 | 312.24 | 338.58 | 361.19 | 379.70 | 392.97 | 403.37 | 413.48 | 423.71 | 436.85 | 439.08 | 440.44 | |
SD | 7.449 | 6.553 | 7.835 | 9.188 | 12.880 | 17.796 | 19.347 | 22.131 | 19.484 | 24.611 | 25.790 | 27.485 | 30.498 | 27.671 | 33.514 | |
1000 | (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Mean | 150.52 | 184.17 | 234.38 | 279.46 | 309.39 | 328.27 | 350.81 | 368.01 | 383.58 | 390.55 | 404.03 | 410.94 | 424.02 | 423.31 | 422.51 | |
SD | 8.754 | 9.976 | 11.711 | 14.016 | 14.065 | 17.230 | 18.047 | 21.311 | 22.239 | 21.757 | 22.808 | 24.090 | 23.699 | 26.428 | 28.406 | |
Females | ||||||||||||||||
Quarantine | Dosing | |||||||||||||||
Dose group [mg/kg bw/d] | Body Weight (g) | Day 8 | Day 1 | Day 8 | Day 15 | Day 22 | Day 29 | Day 36 | Day 43 | Day 50 | Day 57 | Day 64 | Day 71 | Day 78 | Day 85 | Day 92 |
0 | (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Mean | 135.00 | 150.48 | 170.47 | 191.19 | 199.22 | 209.94 | 220.58 | 226.76 | 234.38 | 233.67 | 240.22 | 241.98 | 254.34 | 246.63 | 245.33 | |
SD | 5.712 | 6.915 | 7.833 | 7.542 | 8.350 | 8.647 | 9.924 | 10.203 | 10.886 | 9.719 | 13.347 | 12.840 | 10.667 | 13.681 | 8.958 | |
100 | (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Mean | 135.90 | 150.82 | 169.36 | 187.70 | 196.72 | 209.38 | 216.37 | 222.46 | 228.59 | 234.15 | 233.75 | 237.49 | 241.86 | 241.94 | 240.66 | |
SD | 6.383 | 5.382 | 7.831 | 10.643 | 9.561 | 9.564 | 11.396 | 13.523 | 13.561 | 15.116 | 14.160 | 17.003 | 15.788 | 18.139 | 17.121 | |
300 | (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Mean | 134.63 | 151.08 | 171.75 | 185.76 | 199.71 | 211.50 | 221.59 | 227.10 | 232.45 | 237.24 | 240.17 | 243.19 | 246.98 | 247.21 | 244.47 | |
SD | 5.476 | 5.556 | 9.248 | 11.485 | 13.682 | 15.305 | 17.600 | 17.877 | 15.458 | 18.121 | 17.197 | 17.703 | 18.090 | 18.838 | 15.847 | |
1000 | (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Mean | 133.95 | 149.97 | 170.25 | 188.09 | 199.05 | 212.24 | 217.10 | 222.82 | 230.33 | 232.76 | 236.21 | 239.07 | 244.73 | 245.27 | 242.53 | |
SD | 6.130 | 6.283 | 8.502 | 11.834 | 10.446 | 10.008 | 10.733 | 12.913 | 11.811 | 15.021 | 14.087 | 12.316 | 15.308 | 13.890 | 16.520 |
Table 3: Haematology - Group mean data
Dosing Day 92 | |||||||||||||||||||||||
Males | |||||||||||||||||||||||
Dose group [mg/kg bw/d] | RBC (x10^6/μL) | HGB (g/dL) | HCT (%) | MCV (fL) | MCH (pg) | MCHC (g/dL) | RET (x10^9/L) | RETR (%) | WBC (x10^3/μL) | NEU (x10^3/μL) | LYM (x10^3/μL) | MON (x10^3/μL) | EOS (x10^3/μL) | BAS (x10^3/μL) | LUC (x10^3/μL) | NEUR (%) | LYMR (%) | MONR (%) | EOSR (%) | BASR (%) | LUCR (%) | PLT (x10^3/μL) | |
0 | (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Mean | 8.079 | 14.58 | 44.62 | 55.24 | 18.05 | 32.72 | 159.46 | 1.973 | 5.534 | 0.996 | 4.212 | 0.144 | 0.134 | 0.023 | 0.024 | 17.69 | 76.40 | 2.60 | 2.46 | 0.43 | 0.40 | 921.4 | |
SD | 0.3414 | 0.483 | 2.144 | 1.453 | 0.445 | 0.549 | 10.923 | 0.0945 | 14.595 | 0.7811 | 12.398 | 0.0714 | 0.0591 | 0.0116 | 0.0135 | 10.669 | 10.324 | 1.024 | 0.912 | 0.125 | 0.156 | 92.55 | |
100 | (n) | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
Mean | 8.266 | 14.69 | 44.65 | 54.08 | 17.79 | 32.91 | 157.09 | 1.905 | 5.661 | 1.273 | 3.944 | 0.256+D | 0.131 | 0.026 | 0.025 | 21.31 | 70.85 | 4.60+D | 2.28 | 0.46 | 0.49 | 974.9 | |
SD | 0.3073 | 0.253 | 0.854 | 1.649 | 0.694 | 0.461 | 11.326 | 0.1565 | 13.050 | 0.7806 | 0.5619 | 0.0883 | 0.0336 | 0.0074 | 0.0076 | 7.386 | 6.977 | 1.219 | 0.328 | 0.052 | 0.189 | 50.05 | |
300 | (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Mean | 7.984 | 14.53 | 44.63 | 55.92 | 18.21 | 32.56 | 155.92 | 1.953 | 4.824 | 0.896 | 3.624 | 0.157 | 0.111 | 0.020 | 0.018 | 19.02 | 74.52 | 3.29 | 2.36 | 0.41 | 0.40 | 903.4 | |
SD | 0.3126 | 0.302 | 1.480 | 1.192 | 0.436 | 0.576 | 16.010 | 0.1793 | 0.7799 | 0.1123 | 0.8302 | 0.0499 | 0.0423 | 0.0067 | 0.0114 | 3.993 | 5.568 | 1.043 | 1.112 | 0.137 | 0.249 | 86.77 | |
1000 | (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Mean | 7.683*D | 14.22 | 42.90 | 55.82 | 18.50 | 33.14 | 148.73 | 1.933 | 5.519 | 1.017 | 4.159 | 0.207 | 0.091 | 0.021 | 0.023 | 19.46 | 74.47 | 3.69 | 1.59 | 0.37 | 0.40 | 935.7 | |
SD | 0.4298 | 1.011 | 3.051 | 1.619 | 0.622 | 0.474 | 19.913 | 0.2282 | 14.543 | 0.1484 | Feb 35 | 0.0803 | 0.0384 | 0.0110 | 0.0106 | 4.873 | 4.194 | 0.679 | 0.438 | 0.095 | 0.094 | 73.36 | |
Females | |||||||||||||||||||||||
Dose group [mg/kg bw/d] | RBC (x10^6/μL) | HGB (g/dL) | HCT (%) | MCV (fL) | MCH (pg) | MCHC (g/dL) | RET (x10^9/L) | RETR (%) | WBC (x10^3/μL) | NEU (x10^3/μL) | LYM (x10^3/μL) | MON (x10^3/μL) | EOS (x10^3/μL) | BAS (x10^3/μL) | LUC (x10^3/μL) | NEUR (%) | LYMR (%) | MONR (%) | EOSR (%) | BASR (%) | LUCR (%) | PLT (x10^3/μL) | |
0 | (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Mean | 6.875 | 13.05 | 38.13 | 55.46 | 18.98 | 34.25 | 138.65 | 2.018 | 3.492 | 0.508 | 2.778 | 0.117 | 0.061 | 0.011 | 0.019 | 15.09 | 79.00 | 3.27 | 1.80 | 0.31 | 0.53 | 917.5 | |
SD | 0.4007 | 0.778 | 2.473 | 1.452 | 0.592 | 0.536 | 20.838 | 0.2985 | 0.9954 | 0.1306 | 0.8627 | 0.0546 | 0.0185 | 0.0057 | 0.0074 | 3.724 | 4.034 | 0.865 | 0.494 | 0.129 | 0.164 | 93.98 | |
100 | (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Mean | 6.701 | 12.81 | 37.69 | 56.26 | 19.11 | 33.96 | 151.88 | 2.270 | 4.138 | 0.700 | 3.214 | 0.135 | 0.055 | 0.011 | 0.021 | 16.54 | 78.15 | 3.18 | 1.35*C | 0.29 | 0.49 | 907.9 | |
SD | 0.2601 | 0.549 | 1.448 | 0.844 | 0.489 | 0.455 | 18.582 | 0.3041 | 12.985 | 0.4293 | 0.9394 | 0.0580 | 0.0255 | 0.0088 | 0.0129 | 5.329 | 5.724 | 0.953 | 0.350 | 0.120 | 0.208 | 55.16 | |
300 | (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Mean | 6.702 | 12.73 | 37.25 | 55.60 | 19.04 | 34.23 | 140.63 | 2.102 | 4.194 | 0.624 | 3.305 | 0.147 | 0.080 | 0.015 | 0.024 | 15.31 | 78.32 | 3.56 | 1.92 | 0.30 | 0.60 | 916.1 | |
SD | 0.2528 | 0.400 | 1.363 | 1.349 | 0.425 | 0.306 | 19.689 | 0.3059 | 0.8239 | 0.1198 | 0.7770 | 0.0467 | 0.0306 | 0.0053 | 0.0097 | 4.156 | 4.576 | 0.892 | 0.718 | 0.082 | 0.194 | 73.22 | |
1000 | (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Mean | 6.813 | 13.12 | 38.11 | 55.95 | 19.24 | 34.40 | 153.14 | 2.255 | 4.931*D | 0.754 | 3.873 | 0.186 | 0.065 | 0.017 | 0.034 | 15.47 | 78.48 | 3.66 | 1.34*C | 0.36 | 0.68 | 905.3 | |
SD | 0.3096 | 0.473 | 1.558 | 1.166 | 0.510 | 0.403 | 32.909 | 0.5175 | 10.523 | 0.2249 | 0.8682 | 0.0875 | 0.0178 | 0.0067 | 0.0196 | 4.099 | 4.706 | 1.265 | 0.295 | 0.107 | 0.336 | 101.97 |
HCT: HAEMATOCRIT [%]
RBC: RED BLOOD CELL COUNT [10^6/μL]
HGB: HAEMOGLOBIN [g/dL]
MCV: MEAN RED BLOOD CELL VOLUME [fL]
MCH: MEAN CORPUSCULAR HAEMOGLOBIN [pg]
MCHC: MEAN CORPUSCULAR HAEMOGLOBIN CONCENTRATION [g/dL]
PLT: PLATELETS [10^3/uL]
WBC: WHITE BLOOD CELL COUNT [10^3/uL]
NEUR/NEU: NEUTROPHILS [% or 10^3/μL]
LYMR/LYM. LYMPHOCYTES [% or 10^3/μL]
MONR/MON: MONOCYTES [% or 10^3/μL]
EOSR/EOS: EOSINOPHILS [% or 10^3/μL]
BASR/BAS: BASOPHILS [% or 10^3/μL]
LUCR/LUC: LARGE UNSTAINED CELLS [% or 10^3/μL]
RETR/RET: RETICULOCYTES [% or 10^3/μL]
*D Dunnett LSD Test Significant at the 0.05 level
+D Dunnett LSD Test Significant at the 0.01 level
*C Cochran and Cox Test Significant at the 0.05 level
Table 4: Clinical Chemistry - Group mean data
Dosing Day 92 | |||||||
Males | Females | ||||||
Dose group [mg/kg bw/d] | Cl [nmol/L] | IP [mg/dL] | Group | Cl [nmol/L] | IP [mg/dL] | ||
0 | (n) | 10 | 10 | Control | (n) | 10 | 10 |
Mean | 103.17 | 5.823 | Mean | 104.80 | 6.112 | ||
SD | 0.801 | 0.7791 | SD | 1.209 | 0.8488 | ||
100 | (n) | 10 | 10 | 2 | (n) | 10 | 10 |
Mean | 102.87 | 6.028 | Mean | 105.38 | 6.255 | ||
SD | 0.747 | 0.6315 | SD | 1.936 | 0.7440 | ||
300 | (n) | 10 | 10 | 3 | (n) | 10 | 10 |
Mean | 103.64 | 6.637*D | Mean | 104.70 | 6.687 | ||
SD | 0.670 | 0.5913 | SD | 1.022 | 0.7779 | ||
(n) | 10 | 10 | 4 | (n) | 10 | 10 | |
1000 | Mean | 103.15 | 6.671*D | Mean | 103.06*D | 6.447 | |
SD | 1.084 | 0.6880 | SD | 1.632 | 0.6767 |
Cl: Chloride
IP: inorganic phosphorus
*D Dunnett LSD Test Significant at the 0.05 evel
Table 5: Clinical Chemistry - Historical Control Data
Historical Contral Data | |||||||||
Males | Females | ||||||||
Age: 9-16 weeks | Age: > 16 weeks | Age: 9-16 weeks | Age: > 16 weeks | ||||||
Cl [nmol/L] | IP [mg/dL] | Cl [nmol/L] | IP [mg/dL] | Cl [nmol/L] | IP [mg/dL] | Cl [nmol/L] | IP [mg/dL] | ||
no | 256 | 86 | 369 | 199 | no | 224 | 75 | 385 | 214 |
Mean | 102.7 | 7.53 | 103.4 | 5.81 | Mean | 103.7 | 6.10 | 103.7 | 5.14 |
SD | 2.2 | 0.66 | 2.6 | 1.30 | SD | 2.5 | 1.29 | 2.5 | 0.99 |
Min obs | 93.6 | 5.27 | 96.1 | 4.15 | Min obs | 94.6 | 4.04 | 97.3 | 2.76 |
Max obs | 109.2 | 8.92 | 111.0 | 17.14 | Max obs | 111.1 | 11.67 | 110.8 | 8.16 |
Range min (perc. 5%) | 99.6 | 6.40 | 99.4 | 4.61 | Range min (perc. 5%) | 100.0 | 4.48 | 99.7 | 3.67 |
Range max (perc. 95%) | 105.7 | 8.54 | 107.9 | 6.93 | Range max (perc. 95%) | 107.2 | 7.83 | 107.9 | 6.89 |
Table 6: Thyroid hormones determination - Group mean data
Dosing Day 88 | |||||||||
Males | Females | ||||||||
Dose group [mg/kg bw/d] | T3 [nmol/L] | T4 [nmol/L] | TSH [ng/mL] | Dose group [mg/kg bw/d] | T3 [nmol/L] | T4 [nmol/L] | TSH [ng/mL] | ||
0 | (n) | 10 | 10 | 10 | 0 | (n) | 10 | 10 | 10 |
Mean | 0.953 | 47.1 | 12.68 | Mean | 1.271 | 39.9 | 10.31 | ||
SD | 0.1594 | 3.90 | 5.648 | SD | 0.1453 | 6.57 | 4.047 | ||
100 | (n) | 10 | 10 | 10 | 100 | (n) | 10 | 10 | 10 |
Mean | 0.967 | 48.9 | 11.47 | Mean | 1.224 | 39.4 | 7.16 | ||
SD | 0.1761 | 4.86 | 4.181 | SD | 0.1501 | 5.68 | 1.260 | ||
300 | (n) | 10 | 10 | 10 | 300 | (n) | 10 | 10 | 10 |
Mean | 1.031 | 52.3 | 9.97 | Mean | 1.271 | 38.7 | 8.68 | ||
SD | 0.1263 | 6.73 | 3.345 | SD | 0.1497 | 8.15 | 1.734 | ||
1000 | (n) | 10 | 10 | 10 | 1000 | (n) | 10 | 10 | 10 |
Mean | 1.042 | 52.3 | 11.69 | Mean | 1.346 | 42.5 | 8.71 | ||
SD | 0.2236 | 06.57 | 4.888 | SD | 0.1531 | 3.27 | 2.822 |
Table 7: Estrous Cycle
Group | Stage | Days Seen | Group | Stage | Days Seen | Group | Stage | Days Seen | Group | Stage | Days Seen |
Control | Proestrus | 92 | 100 mg/kg bw/d | Oestrus | 92 | 300 mg/kg bw/d | Dioestrus | 92 | 1000 mg/kg bw/d | Proestrous | 92 |
Oestrus | 92 | Oestrus | 92 | Oestrus | 92 | Oestrus | 92 | ||||
Oestrus | 92 | Oestrus | 92 | Dioestrus | 92 | Oestrus | 92 | ||||
Oestrus | 92 | Oestrus | 92 | Oestrus | 92 | Oestrus | 92 | ||||
Oestrus | 92 | Oestrus | 92 | Dioestrus | 92 | Proestrous | 92 | ||||
Dioestrus | 93 | Oestrus | 93 | Oestrus | 93 | Oestrus | 93 | ||||
Dioestrus | 93 | Metaoestrus | 93 | Oestrus | 93 | Oestrus | 93 | ||||
Oestrus | 93 | Oestrus | 93 | Oestrus | 93 | Oestrus | 93 | ||||
Oestrus | 93 | Oestrus | 93 | Oestrus | 93 | Oestrus | 93 | ||||
Oestrus | 93 | Oestrus | 93 | Oestrus | 93 | Oestrus | 93 |
Table 8: Open Field Observation of Rearing - Group Mean Data
Males | |||||||||||||||
Allocation | Dosing | ||||||||||||||
Dose group [mg/kg bw/d] | Day 2 | Day 3 | Day 10 | Day 17 | Day 24 | Day 31 | Day 38 | Day 45 | Day 52 | Day 59 | Day 66 | Day 73 | Day 80 | Day 89 | |
0 | (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Mean | 10.4 | 6.7 | 8.2 | 12.9 | 12.8 | 8.7 | 9.1 | 6.9 | 7.0 | 6.9 | 7.8 | 11.2 | 5.8 | 6.1 | |
SD | 0.70 | 1.25 | 1.62 | 2.18 | 1.40 | 1.16 | 1.66 | 3.98 | 1.25 | 4.25 | 1.23 | 1.55 | 3.85 | 1.37 | |
100 | (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Mean | 10.6 | 7.2 | 8.5 | 13.8 | 8.4+D | 8.0 | 8.6 | 4.9 | 8.9 | 6.2 | 7.8 | 11.5 | 3.9 | 6.4 | |
SD | 0.52 | 1.32 | 1.05 | 1.55 | 2.12 | 1.70 | 1.31 | 1.52 | 2.33 | 4.83 | 1.40 | 2.22 | 1.79 | 1.43 | |
300 | (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Mean | 11.7 | 8.2 | 8.1 | 14.4 | 7.6+D | 8.3 | 8.7 | 7.1 | 8.9 | 5.7 | .76 | 9.2 | 4.6 | 6.1 | |
SD | 28.126 | 1.69 | 1.52 | 1.26 | 1.07 | 1.42 | 1.06 | 3.38 | 2.42 | 4.99 | 2.07 | 1.23 | 1.90 | 1.60 | |
1000 | (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Mean | 12.7+C | 6.8 | 7.6 | 13.0 | 8.4+D | 8.3 | 8.4 | 6.4 | 7.8 | 5.1 | 5.8 | 7.3+D | 5.3 | 7.7 | |
SD | 44.714 | 1.32 | 0.84 | 1.49 | 1.17 | 1.57 | 1.51 | 2.41 | 1.62 | 1.91 | 2.97 | 2.83 | 2.58 | 1.77 | |
Females | |||||||||||||||
Allocation | Dosing | ||||||||||||||
Dose group [mg/kg bw/d] | Day 5 | Day 4 | Day 11 | Day 18 | Day 25 | Day 32 | Day 39 | Day 46 | Day 53 | Day 60 | Day 67 | Day 74 | Day 81 | Day 90 | |
0 | (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Mean | 15.1 | 16.5 | 17.2 | 13.9 | 14.2 | 14.9 | 13.9 | 12.2 | 12.9 | 12.5 | 15.5 | 17.6 | 12.1 | 12.0 | |
SD | 24.108 | 1.58 | 1.23 | 1.52 | 1.81 | 5.97 | 3.41 | 3.36 | 2.69 | 1.96 | 1.08 | 1.17 | 2.38 | 2.45 | |
100 | (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Mean | 15.5 | 16.4 | 17.5 | 14.4 | 12.9 | 16.1 | 12.4 | 13.1 | 13.0 | 13.1 | 15.9 | 16.1*D | 11.6 | 11.8 | |
SD | 16.132 | 1.17 | 1.96 | 0.84 | 2.77 | 8.05 | 3.60 | 3.93 | 2.98 | 2.28 | 1.20 | 0.74 | 2.22 | 2.04 | |
300 | (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Mean | 13.6 | 16.7 | 17.2 | 14.6 | 13.3 | 14.6 | 14.4 | 12.8 | 13.5 | 13.2 | 15.6 | 16.6 | 12.2 | 12.3 | |
SD | 27.791 | 2.00 | 1.62 | 1.17 | 2.98 | 5.58 | 2.72 | 2.57 | 2.27 | 2.10 | 1.07 | 1.43 | 2.10 | 1.49 | |
1000 | (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Mean | 16.1 | 15.6 | 14.6+D | 14.5 | 13.7 | 14.6 | 11.2 | 13.5 | 12.6 | 13.8 | 16.0 | 15.5+D | 12.5 | 12.2 | |
SD | 23.408 | 1.84 | 1.51 | 1.18 | 2.83 | 5.25 | 4.29 | 2.80 | 2.27 | 2.57 | 2.11 | 0.97 | 1.65 | 2.30 |
*D Dunnett LSD Test Significant at the 0.05 level
+C Cochran and Cox Test Significant at the 0.01 level
+D Dunnett LSD Test Significant at the 0.01 level
Table 9: Sensory Reactivity / Grip Strength - Group Mean Data
Dosing Day 85 | |||||||||
Males | Females | ||||||||
Dose group [mg/kg bw/d] | GS1 (N) | GS2 (N) | GSME | Dose group [mg/kg bw/d] | GS1 (N) | GS2 (N) | GSME | ||
0 | (n) | 10 | 10 | 10 | 0 | (n) | 10 | 10 | 10 |
Mean | 17.23 | 17.75 | 17.490 | Mean | 46.631 | 13.394 | 9.315 | ||
SD | 2.222 | 2.693 | 22.704 | SD | 1.143 | 1.342 | 0.8377 | ||
100 | (n) | 10 | 10 | 10 | 100 | (n) | 10 | 10 | 10 |
Mean | 18.38 | 17.20 | 17.790 | Mean | 22.920 | 28.004 | 10.190*D | ||
SD | 2.407 | 2.710 | 20.556 | SD | 1.558 | 1.081 | 0.3658 | ||
300 | (n) | 10 | 10 | 10 | 300 | (n) | 10 | 10 | 10 |
Mean | 15.18*C | 14.52+C | 14.850+C | Mean | 11.46+D | 11.43+D | 11.445+D | ||
SD | 0.985 | 1.347 | 10.376 | SD | 1.078 | 1.461 | 0.7798 | ||
1000 | (n) | 10 | 10 | 10 | 1000 | (n) | 10 | 10 | 10 |
Mean | 15.51*C | 15.43*C | 15.470*C | Mean | 11.63+D | 10.95*D | 11.290+D | ||
SD | 0.825 | 0.525 | 0.4911 | SD | 1.237 | 1.313 | 0.5962 |
GS1 (N): Grip strength 1 (N) - First reading of the animal grips on horizontal bar with forelimbs.
GS2 (N): Grip strength 2 (N) - Second reading of the animal grips on horizontal bar with forelimbs.
GSME (N): Grip strength mean (N) - Averaged reading of the animal grips on horizontal bar with forelimbs.
*C Cochran and Cox Test Significant at the 0.05 level
+C Cochran and Cox Test Significant at the 0.01 level
*D Dunnett LSD Test Significant at the 0.05 level
+D Dunnett LSD Test Significant at the 0.01 level
Table 10: Organ Weights (absolute) - Group Mean Data
Males | ||||||||||||||
Dose group [mg/kg bw/d] | Terminal Body Weight (g) | Adrenal glands (g) | Brain (g) | Epididymides (g) | Heart (g) | Kidneys (g) | Liver (g) | Pituitary gland (g) | Seminal vesicales (g) | Spleen (g) | Testes (g) | Thymus (g) | Thyroid gland (g) | |
0 | (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Mean | 418.76 | 0.0572 | 1.885 | 1.4884 | 1.459 | 2.842 | 11.345 | 0.0102 | 29.367 | 0.8516 | 3.9880 | 0.3878 | 0.0250 | |
SD | 15.148 | 0.01070 | 0.1062 | 0.11589 | 0.0994 | 0.2256 | 0.9340 | 0.00148 | 0.25547 | 0.12309 | 0.20227 | 0.08863 | 0.00279 | |
100 | (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Mean | 430.83 | 0.0547 | 1.820 | 1.4204 | 1.465 | 2.952 | 11.160 | 0.0101 | 29.149 | 0.8168 | 3.8698 | 0.3823 | 0.0254 | |
SD | 24.456 | 0.00699 | 0.1194 | 0.16700 | 0.1052 | 0.2185 | 0.6929 | 0.00218 | 0.45206 | 0.12634 | 0.26608 | 0.04932 | 0.00334 | |
300 | (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Mean | 423.03 | 0.0550 | 1.843 | 1.4501 | 1.436 | 2.900 | 11.166 | 0.0101 | 29.547 | 0.8298 | 4.0772 | 0.3749 | 0.0250 | |
SD | 27.223 | 0.00600 | 0.1124 | 0.15832 | 0.1017 | 0.1419 | 11.351 | 0.00166 | 0.31716 | 0.08952 | 0.19436 | 0.05875 | 0.00397 | |
1000 | (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Mean | 404.63 | 0.0550 | 1.794 | 1.4148 | 1.398 | 2.772 | 10.791 | 0.0100 | 28.722 | 0.7834 | 3.9353 | 0.4010 | 0.0245 | |
SD | 28.862 | 0.00884 | 0.1249 | 0.13708 | 0.1339 | 0.2906 | 0.8977 | 0.00216 | 0.38276 | 0.09060 | 0.24511 | 0.08568 | 0.00375 | |
Females | ||||||||||||||
Dose group [mg/kg bw/d] | Terminal Body Weight (g) | Adrenal glands (g) | Brain (g) | Heart (g) | Kidneys (g) | Liver (g) | Ovaries (g) | Pituitary gland (g) | Spleen (g) | Thymus (g) | Thyroid gland (g) | Uterus (g) | - | |
0 | (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | |
Mean | 235.09 | 0.0621 | 1.624 | 0.887 | 1.597 | 5.796 | 0.1024 | 0.0123 | 0.5286 | 0.2671 | 0.0217 | 0.9126 | ||
SD | 11.252 | 0.00588 | 0.0884 | 0.0855 | 0.1237 | 0.5074 | 0.01935 | 0.00275 | 0.04218 | 0.02162 | 0.00460 | 0.36216 | ||
100 | (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | |
Mean | 227.46 | 0.0617 | 1.606 | 0.886 | 1.461 | 5.470 | 0.1005 | 0.0120 | 0.5095 | 0.2409 | 0.0211 | 11.748 | ||
SD | 17.237 | 0.01185 | 0.1280 | 0.0714 | 0.1195 | 0.4864 | 0.01757 | 0.00211 | 0.07715 | 0.05443 | 0.00491 | 0.75968 | ||
300 | (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | |
Mean | 233.98 | 0.0657 | 1.652 | 0.888 | 1.569 | 5.738 | 0.1143 | 0.0133 | 0.5451 | 0.2311 | 0.0226 | 0.9112 | ||
SD | 17.012 | 0.00950 | 0.0965 | 0.0472 | 0.1323 | 0.5901 | 0.02086 | 0.00245 | 0.04320 | 0.03127 | 0.00517 | 0.47996 | ||
1000 | (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | |
Mean | 229.27 | 0.0634 | 1.628 | 0.933 | 1.594 | 5.759 | 0.1003 | 0.0132 | 0.5461 | 0.2575 | 0.0255 | 1.0257 | ||
SD | 12.813 | 0.00996 | 0.1003 | 0.0970 | 0.1693 | 0.4818 | 0.01824 | 0.00429 | 0.08310 | 0.04852 | 0.00357 | 0.84612 |
Table 11: Microscopic observations
Incidence and severity of selected microscopic findings (End of Treatment) | ||||||||
Gender | Males | Females | ||||||
Group | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 |
Dose (mg/kg bw/d) | 0 | 100 | 300 | 1000 | 0 | 100 | 300 | 1000 |
Mesenteric lymph node | ||||||||
Aggregates, macrophages | ||||||||
Examined | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Absent | 10 | 10 | 10 | 2 | 10 | 10 | 9 | 1 |
Minimal | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 6 |
Slight | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 3 |
Moderate | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
Uterus | ||||||||
Squamous metaplasia | ||||||||
Examined | NA | NA | NA | NA | 10 | 10 | 10 | 10 |
Absent | - | - | - | - | 7 | 6 | 7 | 3 |
Minimal | - | - | - | - | 1 | 2 | 2 | 2 |
Slight | - | - | - | - | 1 | 1 | 1 | 2 |
Moderate | 1 | 1 | 0 | 3 |
NA: not applicable
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Repeated dose - 13 weeks (OECD408):
No adverse effects were observed in a GLP compliant OECD 408 study in rats at dose levels of 100, 300, 1000 mg/kg bw with an oral administration of 13 consecutive weeks in male and female animals. The test material was dosed by gavage as a suspension in aqueous carboxymethyl cellulose (0.5%). The OECD 422 study (described below) served as a dose range finding study.
The following investigations were performed: mortality and morbidity check, daily clinical signs, weekly detailed clinical signs (removal from cage and open field observations), evaluation of sensory reactivity to stimuli and motor activity, body weight, food consumption, oestrus cycle evaluation, ophthalmoscopy, clinical pathology investigations (including haematology and coagulation, clinical chemistry and thyroid hormones determination), terminal body weight, organ weights, macroscopic observations and microscopic examination, which included the identification of the stages of the spermatogenic cycle and the evaluation of the staining of the oestrus cycle.
Neither mortality nor treatment-related clinical signs were observed throughout the course of the study. Furthermore, neurotoxicity assessment including open field measurements and motor activity assessment did not reveal any treatment-related changes. Upon necropsy, body weights, organ weights, ophthalmoscopic and macroscopic examination did not show any treatment-related findings. Coagulation and thyroid hormone measurements were without treatment-related findings. Changes observed in hematological and clinical chemistry examinations were within the range of the laboratory's historical control data. In high dose males, a decreased in erythrocytes was observed of -5%, which was in 5/10 animals below the historical control values for this parameter. However, due to the slight severity of this finding, it was considered not adverse even though a relation with treatment could not be definitively excluded.
Microscopic examination of tissues showed aggregates of large macrophages in the mesenteric lymph nodes of both sexes at the dose of 1000 mg/kg/day, and in a single female at the dose of 300 mg/kg/day. In the absence of other changes in the node architecture and of associated clinical pathology changes, this finding was considered non-adverse. A higher incidence of squamous metaplasia of the uterus was observed at 1000 mg/kg/day, in a context of an unusually high prevalence of the change in the study, including in control animals. Additionally, no differences in ovarian cycle distribution were observed between control and high dose animals. The increased squamous metaplasia of the uterine glands was therefore considered a chance event, unrelated to the test item.
On the basis of these results, no adverse effects were observed at all dose levels investigated following treatment with the test substance when administered by oral gavage for 13 consecutive weeks at the dosages of 100, 300 and 1000 mg/kg/day, when compared to controls. Therefore, it can be concluded that the No Observed Adverse Effect Level (NOAEL) for this study is 1000 mg/kg/day.
Repeated dose - Reprotox Screening (OECD422):
No adverse effects were observed in the GLP compliant OECD 422 study in rats at the nominal doses of 100, 300 and 1000 mg/kg bw, including the 14-day postobservation groups for the high dose and control group animals. The test material was dosed by gavage as a suspension in aqueous carboxymethyl cellulose (0.5%).
The study was performed according to the OECD testing guideline in its version of 2016. This involves a longer treatment of females to account for the longer observation of pups.
No treatment-related finding was observed for any parameter.
The test material was found to be stable in formulations for 7 days and to be homogenously distributed. Aliquots of dosing samples taken throughout the study were frozen and analysed later versus a standard of the solid test material. The mean recovery was 84% indicating that the acutal dosed volume might have been only up to 840 mg/kg bw. As no spiked storage control samples were included, loss of the absorbing test material during storage might explain the lower recovery. Considering the absence of adverse effects, this does not give rise of an undetected hazard.
In the 14-day dose-range finding study in rats, no adverse clinical signs were noted during treatment with 300 or 1000 mg/kg bw. Body weight gain was not affected. Weights of assessed organs (liver, spleen, kidney, adrenal gland) were within the normal range. The substance was applied as a suspension in aqueous carboxymethyl cellulose.
Justification for classification or non-classification
Classification, Labelling, and Packaging Regulation (EC) No. 1272/2008
The available experimental test data are reliable and suitable for classification purposes under Regulation 1272/2008. No adverse effects were observed at doses up to 1000 mg/kg bw in subacute and subchronic oral toxicity studies in rats. Since there were no significant toxic effects at doses of less than 300 mg/kg bw upon subacute oral exposure in rats the substance does not need to be classified for repeated dose toxicity under Regulation (EC) No. 1272/2008, as amended for the fourteenth time in Regulation (EC) No. 2020/217.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.